ERBB2 and breast carcinoma: However, in 2004, Meng et al (2004) demonstrated that HER2 gene amplification can be acquired as breast cancer progresses; this concurs with results using immunocytochemistry of circulating tumour cells (Wulfing et al, 2006) showing that 50% of patients had evidence of HER2-positive cells in the blood and that this correlated with survival; the proportion of positive cells exceeded that expected by IHC of the primary tumour.